Samsung Biologics, Eli Lilly team up to launch major biotech hub in Korea

The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms

Johnson & Johnson reports promising early results for targeted bladder cancer therapy

FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors

Glenmark Pharmaceuticals USA to launch Potassium Phosphates Injection USP in multiple vial sizes

The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days

Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

The early-stage study will test the drug’s safety, tolerability and biological effects in humans

Biogen unveils promising new data for Salanersen in kids with SMA

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains

Caplin Steriles gets USFDA approval for potassium phosphates injection

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions

Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

Marks significant milestone for breakthrough biologic to treat rare blood cancers

Kainova reports positive Phase I results for receptor antagonist targeting advanced tumors

Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile